| Nov 14 |
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
|
| Nov 13 |
Tourmaline Bio, Inc. Reports Third Quarter Financial Results
|
| Nov 7 |
Tourmaline Bio files for $350M mixed securities shelf
|
| Nov 7 |
Talaris Therapeutics GAAP EPS of -$0.78 beats by $0.05
|
| Nov 7 |
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Oct 15 |
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
|
| Oct 13 |
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
|
| Oct 11 |
Tourmaline Bio stock slides 7% amid news of CMO's departure
|
| Oct 11 |
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
|
| Sep 3 |
Tourmaline Bio to Present at Upcoming Investor Conferences
|
